Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK1D | P48730 | 11/20 | 0.34 |
| ▸ | CSNK1E | P49674 | 11/20 | 0.34 |
| ▸ | CFTR | P13569 | 3/20 | 0.33 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.32 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.32 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.31 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.31 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.31 |
| ▸ | PADI4 | Q9UM07 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24985127 | 0.92 | CFTR (0.33) | CSNK1DCSNK1ECFTRIRAK1IRAK4 | |
| SCHEMBL24985131 | 0.92 | CFTR (0.33) | CSNK1DCSNK1ECFTRIRAK1IRAK4 | |
| SCHEMBL24986157 | 0.90 | CFTR (0.32) | CSNK1DCSNK1ECFTRIRAK1IRAK4 | |
| SCHEMBL29620739 | 0.90 | CSNK1D (0.31) | CSNK1DCSNK1ECFTRIRAK1IRAK4 | |
| SCHEMBL24345446 | 0.90 | CSNK1D (0.31) | CSNK1DCSNK1ECFTRIRAK1IRAK4 | |
| SCHEMBL24345854 | 0.90 | CFTR (0.33) | CSNK1DCSNK1ECFTRIRAK1IRAK4 | |
| SCHEMBL24988279 | 0.89 | CFTR (0.35) | CSNK1DCSNK1ECFTRIRAK1IRAK4 | |
| SCHEMBL24988280 | 0.89 | CFTR (0.35) | CSNK1DCSNK1ECFTRIRAK1IRAK4 | |
| SCHEMBL24345669 | 0.87 | POLB (0.38) | CFTRADORA2AADORA2BADORA1KMT2A | |
| SCHEMBL24345270 | 0.87 | POLB (0.38) | CFTRADORA2AADORA2BADORA1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220119398-A1 | HETEROCYCLIC COMPOUNDS AS ANTI-VIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2022-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220119398-A1 | HETEROCYCLIC COMPOUNDS AS ANTI-VIRAL AGENTS | VIP, ACE, FURIN | CSNK1D 3744/4885CSNK1E 3071/4885CFTR 307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.